Have a feature idea you'd love to see implemented?
Let us know!
GANX Gain Therapeutics Inc
Price (delayed)
$2.08
Market cap
$55.17M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.1
Enterprise value
$43.89M
Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new
Highlights
The EPS has grown by 39% YoY and by 15% from the previous quarter
Gain Therapeutics's debt has decreased by 26% YoY and by 4.7% QoQ
GANX's equity is down by 24% since the previous quarter but it is up by 22% year-on-year
Gain Therapeutics's gross profit has shrunk by 100% YoY
GANX's revenue has plunged by 100% YoY
Key stats
What are the main financial stats of GANX
Market
Valuations
Earnings
Shares outstanding
26.53M
Market cap
$55.17M
Enterprise value
$43.89M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.96
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$21.37M
EBIT
-$21.32M
EBITDA
-$21.23M
Free cash flow
-$21.1M
Per share
Balance sheet
Liquidity
EPS
-$1.1
EPS diluted
-$1.1
Free cash flow per share
-$0.8
Book value per share
$0.35
Revenue per share
$0
TBVPS
$0.54
Total assets
$14.37M
Total liabilities
$5.46M
Debt
$769,413
Equity
$8.91M
Working capital
$9.15M
Debt to equity
0.09
Current ratio
2.99
Quick ratio
2.62
Net debt/EBITDA
0.53
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-128%
Return on equity
-203.9%
Return on invested capital
N/A
Return on capital employed
-218.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GANX stock price
How has the Gain Therapeutics stock price performed over time
Intraday
-5.02%
1 week
-8.37%
1 month
27.61%
1 year
-40.4%
YTD
-3.7%
QTD
-3.7%
Financial performance
How have Gain Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$21.43M
Net income
-$21.37M
Gross margin
N/A
Net margin
N/A
Gain Therapeutics's gross profit has shrunk by 100% YoY
GANX's revenue has plunged by 100% YoY
GANX's operating income is up by 4.4% YoY
The net income is up by 3.8% year-on-year
Growth
What is Gain Therapeutics's growth rate over time
Valuation
What is Gain Therapeutics stock price valuation
P/E
N/A
P/B
5.96
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 39% YoY and by 15% from the previous quarter
The stock's price to book (P/B) is 35% more than its last 4 quarters average of 4.4
GANX's equity is down by 24% since the previous quarter but it is up by 22% year-on-year
GANX's revenue has plunged by 100% YoY
Efficiency
How efficient is Gain Therapeutics business performance
Gain Therapeutics's return on equity has decreased by 20% YoY but it has increased by 4.8% QoQ
GANX's return on assets is down by 12% year-on-year
Dividends
What is GANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GANX.
Financial health
How did Gain Therapeutics financials performed over time
GANX's total assets is 163% greater than its total liabilities
GANX's current ratio is up by 30% year-on-year and by 5% since the previous quarter
Gain Therapeutics's total liabilities has decreased by 26% from the previous quarter and by 19% YoY
Gain Therapeutics's debt is 91% lower than its equity
GANX's debt to equity is down by 36% year-on-year but it is up by 29% since the previous quarter
Gain Therapeutics's debt has decreased by 26% YoY and by 4.7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.